Building a Global BK Community
A conversation about how to build a broader BK community of writers, customers, practitioners, and other stakeholders--with a special focus on the Asia-Pacific Region.
Created by Alvina Jennifer
The Global Meningococcal Vaccines Market Research Report has analysed the 2013 market and made predictions for the next four years. Key players are expected to continue to lead the industry, but newcomers are not to be ignored.
The Global Meningococcal Vaccines Market Research Report was published and outlined the foreseeable growth of the market up until 2022. The report detailed global and regional markets with explanation of expected growth in the meningococcal vaccine industry in particular areas.
What the report covered
The report begins with market definitions and an overview of the global market and related technologies. This is followed by an analysis of the market status and global trends, particularly over the past five years. It features data from 2013, estimations from 2014 and 2015 and projections up to 2022.
The report examines regions including North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. To discuss the market geographically, it is further segmented into countries such as Canada, India, Japan, China and Germany.
There are many driving factors of the report including:
Along with restraining factors, such as:
Possibly the biggest finding of the report is estimations the Global Meningococcal Vaccines Market is expected to surpass US $4 billion by 2022 and will also expand at a compound annual growth rate (CAGR) of approximately 12 per cent over the next four years. This allows new market opportunities to be identified and promotional plans for the market to be put in place.
The research report then discusses research and development as well as the demand for new products. The authors reveal the industry’s expected top companies for the upcoming years, accompanied by comprehensive company profiles.
Notable key players mentioned in the report are:
While big brands of vaccines themselves include:
Meningococcal Strain B Vaccines
Has there been any change since the report was released?
Pharmaceutical company Pfizer is already taking action by working with public health officials in Thailand to devise new ways to deploy vaccines amid shortfalls in the nation’s health funding.
According to Luksanawan Thangpaiboolm, head of the company’s vaccine unit in Thailand and Indochina: “Pfizer believes it can significantly alleviate the problems facing the country’s overstretched health services.”
In 2017, the $129 billion set aside in Thailand’s Public Health Ministry’s budget did not cover the $142 billion required to meet demand. On the back of this, the Thailand Development Research Institute (TDRI) has issued a warning that the country will need $1.4 trillion for public health in a decade’s time, which it will not be able to acquire.
Pfizer has a number of available vaccines it is working to deploy to Thailand, including the new breakthrough vaccination for pneumococcal disease, an illness caused by Streptococcus bacteria. Luksanawan mentioned the vaccine is currently available in hospitals across the country but at the moment, costs associated with administering the drug cannot be reimbursed.
Will the top companies be able to handle the growth?
With an expected growth predicted for the top companies, it can only be questioned whether they will be prepared for increased demand. After all, it would not be the first time leaders in the industry have faced a shortage.
An example is the relatively new vaccine able to protect children against meningococcal strain B, Bexsero. In 2016, pharmaceutical giant GlaxoSmithKline announced the vaccine was in short supply across the globe until early 2017.
This shortage reportedly led countries, including the United Kingdom and Ireland, to include the Bexsero vaccine as part of their national immunisation programs – but due to the higher demand, the short supply available and the cost, the meningococcal-B vaccine is often reserved for children at increased risk of contracting the disease. According to Dr Ryan Harvey at House Call Doctor, these examples include children who have been exposed to meningococcal at child care or school.
The Global Meningococcal Vaccines Market Research Report has reiterated the dominance of the industry’s top companies – but with an increased demand for new products and a risk leaders will struggle meeting predicted growth levels, there is an opening for newcomers to make their mark.